Category Archives: MS Treatment

Los Angeles, CA (PRWEB) August 07, 2012 Promises West L.A. is pleased to introduce its newly appointed executive director, Kelly M. Seidlitz. Drawing on Mr. Seidlitzs wealth of experience working with adolescents and young adults, Promises West L.A. will focus on treating young adults with substance abuse and mental health issues. Mr. Seidlitz brings more than 10 years of administrative, clinical and managerial experience in chemical dependency and mental health treatment to this role. He holds a masters degree in psychology with a specialization in addiction as well as a drug and alcohol counselor certification and a juris doctorate from Gonzaga University. Prior to joining Promises, he served as a Chemical Dependency Professional at an adolescent drug rehab center, a Program Manager at an adolescent prison and Program Director at a residential addiction treatment program in Malibu. Trained by Marsha Linehan and her team in Dialectical Behavior Therapy (DBT), Mr. Seidlitz has successfully implemented DBT programs in a number of settings, including an adolescent psychiatric unit, an adolescent prison, a residential drug rehab center, and in his own home where he and his wife provided therapeutic foster care for six emotionally and behaviorally disordered children for over 10 years. Kelly … Continue reading →

ATLANTA, GA--(Marketwire -08/06/12)- Sharecare, an interactive health and wellness social platform providing access to expert-developed answers, health information and programs, today announced that the Cancer Treatment Centers of America (CTCA) has joined its robust network of experts as a new content collaborator. Through the Sharecare platform, CTCA professionals will provide easily accessible information online about all topics related to cancer and cancer treatments for patients and their loved ones. The partnership between CTCA and Sharecare enables cancer patients to have easy access to CTCA's wealth of experts online, who are available to answer all questions related to the hundreds of treatment options, including: chemotherapy, mind-body medicine, radiation therapy, nutrition therapy, naturopathic medicine, surgical oncology, and acupuncture. The CTCA also connects patients to hospitals across the country that specialize in cancer care. "We're excited to extend our online reach through the Sharecare platform to provide patients living with advanced and complex cancer the credible information they need to help make treatment decisions that are best for them," said Chris Hamrick, director of public affairs at the CTCA. Cancer is the second most common cause of death in the United States, exceeded only by heart disease, accounting for nearly 1 of every … Continue reading →

Component of sea anemone venom about to start clinical trials Sea anemones use venomous stinging tentacles to stun their prey, but one component of that venom is being used by researchers to treat the debilitating effects of Multiple Sclerosis (MS). A new class of drug treatment is about to commence clinical trials, as the result of a decade-long investigation by Professor Ray Norton, from the Monash Institute of Pharmaceutical Sciences and his collaborators, who in the mid 1990s found a component of venom called ShK in the Caribbean sea anemone. The researchers found ShK blocks the Kv1.3 potassium channel located in white blood cells, known as T-cells, which are known to produce nerve damage in MS, one of the most common and debilitating diseases of the nervous system. Professor Norton has since collaborated with a team of scientists in the United States investigating potassium channels as targets for the development of novel immunosuppressive agents. With potassium channels controlling all sorts of key functions in the human body, developing a drug without unwanted side effects would have been impossible had it not turned out that the Kv1.3 potassium channel is found only on T-cells and in the nose. Because of this … Continue reading →

The husband of a woman who died of complications from multiple sclerosis is angry MS patients who receive provincially funded liberation therapy treatment in New York state are entitled to follow up care in Saskatchewan, but patients who pay for the treatment out of their own pockets are not. "My wife had the same procedure and so have hundreds of other people in Saskatchewan and all we're asking for is the same thing," Vince Garland said Thursday. For several years, his wife, Roxane, battled MS. The 37-year-old died July 22 from complications that included a bladder infection. Vince said the home care nurses were excellent, but he is frustrated nurse practitioners and doctors aren't part of the home care team. He said that would ease the process of getting lab tests and scans ordered. The couple spent around $40,000 so Roxane could have two liberation treatments in Mexico in 2010 and one in California the next year. The couple didn't expect a cure, but Vince said it was worth the money because Roxane got relief from some symptoms. Michelle Walsh, an MS patient who has gone to Bulgaria and California for treatment, is a friend of Garland and is advocating … Continue reading →

Vince Garland is angry patients with multiple sclerosis who receive provincially funded Liberation Therapy treatment in New York state are entitled to followup care after the procedure, but not patients who pay for the treatment out of their own pockets. "My wife had the same procedure and so have hundreds of other people in Saskatchewan and all we're asking for is the same thing," Garland said Thursday. For several years, his wife, Roxane, battled MS. The 37-year-old died July 22 from complications that included a bladder infection. Vince said the homecare nurses were excellent, but he is frustrated nurse practitioners and doctors aren't part of the homecare team. That would ease the process of getting lab tests and scans ordered. The couple spent around $40,000 so Roxane could have two Liberation treatments in Mexico in 2010 and one in California the next year. The couple didn't expect a cure, but Vince said it was worth the money because Roxane got relief from some symptoms. Michelle Walsh, an MS patient who has gone to Bulgaria and California for treatment, is a friend of Garland and is advocating for improved treatment. She said by the time Roxane was taken to hospital and … Continue reading →

Chief Minister Katy Gallagher has confirmed she met the woman behind the Canberra Hospital data tampering scandal during a 2010 holiday in France. In April the staffer admitted changing data to make treatment times in the emergency department look better. She has since resigned. Ms Gallagher says while on leave she stayed with her her sister in France, who was also on holiday there. Ms Gallagher says the staffer, a friend of her sister, also visited. "I have provided all of this information to the Auditor General. I have provided this information to the Solicitor General and I sought advice around how to handle this going forward and from my point of view I've made that information clear," she said. "The investigation has happened and it's cleared me of any involvement in any direct or indirect way and I think that gets lost in all of this." But the ACT Opposition has accused the Chief Minister of deceiving the public. Liberal's Jeremy Hanson says Ms Gallagher has not been up-front. "Why was she hiding this personal relationship? What else is there that Katy Gallagher hasn't told us about this scandal?" he said. See the original post: Chief Minister denies French … Continue reading →

ScienceDaily (July 31, 2012) Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment. B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce immunoglobulins, proteins that serve as antibodies. The B cells appear to have other functions, including helping to regulate other lymphocytes, particularly T cells, and helping maintain normal immune function when healthy. In patients with MS, the B cells appear to attack the brain and spinal cord, possibly because there are substances produced in the nervous system and the meninges -- the covering of the brain and spinal cord -- that attract them. Once within the meninges or central nervous system, Lisak said, the activated B cells secrete one or more substances that do not seem to be immunoglobulins but that damage oligodendrocytes, the cells that produce a … Continue reading →

SAN FRANCISCO, CA--(Marketwire -07/31/12)- Unity Technologies, provider of the Unity multi-platform game engine and development tools, announced the Unity Pro MS&T Bundle. The collection of Unity tools will be the first of its kind for Unity Technologies and signifies their dedication to meeting specific needs of the MS&T development community in one package. Unity, an intuitive and powerful engine and toolset for interactive 3D development, has been used to create thousands of games for entertainment along with an ever-increasing number of serious games, computer based training, distributed learning, virtual worlds, data visualization, interactive multimedia instruction, virtual medical training and task management training applications. The Unity Pro MS&T Bundle was designed for the significant number of development studios outside of the entertainment sector, many of which are specifically devoted to simulation and training programs. JANUS Research Group, Inc., an industry leader in Serious Games and Interactive Multimedia Instruction, has been developing solutions with Unity over the past seven years. "We are very excited about the MS&T bundle offering as it includes several domain relevant features such as Geographic Information Systems (GIS) data Import and SCORM," said Clint Little, Serious Games Director, Engineering and Innovation Division, JANUS Research Group, Inc. "We look … Continue reading →

Public release date: 31-Jul-2012 [ | E-mail | Share ] Contact: Julie O'Connor julie.oconnor@wayne.edu 313-577-8845 Wayne State University - Office of the Vice President for Research DETROIT -- Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment. B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce immunoglobulins, proteins that serve as antibodies. The B cells appear to have other functions, including helping to regulate other lymphocytes, particularly T cells, and helping maintain normal immune function when healthy. In patients with MS, the B cells appear to attack the brain and spinal cord, possibly because there are substances produced in the nervous system and the meninges the covering of the brain and spinal cord that attract them. Once within the meninges or central nervous system, Lisak said, the activated B … Continue reading →

NHS funding for a groundbreaking drug piloted in the North East for patients with multiple sclerosis is now mandatory. The National Institute for Clinical Excellence (Nice) has stipulated that adults with relapsing remitting MS not responding to treatment with first-line interferon injections should have access to fingolimod, an oral pill that cuts relapses by more than half compared to a standard injection. Clinical trials that began in 2004 at the regional centre for the treatment of MS at Newcastles Royal Victoria Infirmary (RVI) has meant patients in the North East were among the first worldwide to try fingolimod. Now all eligible patients should have access to the daily pill, which is proven to be twice as effective as a standard injection. Dr Martin Duddy, consultant neurologist at the RVI said: A number of patients at our centre have already started treatment with fingolimod and we anticipate these numbers will increase over the coming months. Our patients are keen to get started on treatment and we are delighted to be one of the first centres in the UK to have our service up and running. It is an important step forward and it gives us another option in the treatment for … Continue reading →